EMCURE PHARMACEUTICALS L
Momentum (86/100) does the heavy lifting; valuation (45/100) is the drag.
Fair valueEMCURE PHARMACEUTICALS L earns a Buy from StocksWizard, with a blended score of 65/100. On 37.8x trailing earnings it sits roughly in line with the Healthcare median of about 37.6x. It's trading right at its 52-week high of ₹1,960.1. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. The average analyst target of ₹1,913.5 implies about 2% downside across 6 analysts. It clears 9 of 13 investability checks, with durability 64, valuation 47 and momentum 86 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹1,498.74.
Analyst views
1-year price
EOD · 2026-07-3152-week range
+0.00% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Buy65Piotroski F-score 4/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 19.6%
- Pass: Low debt (D/E < 0.5): 0.31x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 17%
- Pass: Earnings growing: 29%
- Pass: Net margin ≥ 10%: 10.0%
- Fail: Current ratio > 1.5: 1.43
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 6.17
- Fail: Piotroski ≥ 7: 4/9
Quarterly results
Annual financials
Shareholding
- Promoter81.7%
- Institutions5.4%
- Public & other12.9%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Strong return on equity (19.6%).
- Lightly leveraged balance sheet.
- Trading near its 52-week high.
- Financially solid — Altman Z 6.17.
Opportunities
- Earnings growing (29% YoY).
- Revenue growing (17% YoY).
About EMCURE PHARMACEUTICALS L
Emcure Pharmaceuticals Limited manufactures and distributes pharmaceutical products across multiple therapeutic areas including gynecology, anti-infectives, pain management, vitamins and minerals, oncology, respiratory, HIV antivirals, gastroenterology, anti-diabetes, neurology, and cardiovascular treatments. The company markets its products under brand names including Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym.
EMCURE PHARMACEUTICALS L — frequently asked questions
Is EMCURE PHARMACEUTICALS L a buy, hold or sell?
StocksWizard currently rates EMCURE PHARMACEUTICALS L (EMCURE) a Buy, based on a blended score of 65/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is EMCURE PHARMACEUTICALS L's fair value?
Our blended DCF and relative-valuation model estimates EMCURE PHARMACEUTICALS L's fair value at about ₹1,873.42, versus a current price of ₹1,960.1 — roughly 4% downside. On that basis the stock looks fairly valued.
Is EMCURE PHARMACEUTICALS L financially healthy?
EMCURE PHARMACEUTICALS L scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.
How has EMCURE PHARMACEUTICALS L's share price performed?
EMCURE PHARMACEUTICALS L is up 16% over three months, and last traded at ₹1,960.1. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.